调整希罗达加奥沙利铂给药时间化疗中晚期结直肠癌  

Chronomodulated Administration of Oxaliplatin Plus Capecitabine(XELOX) in Patients with Advanced Colorectal Cancer

作　　者：欧阳一鸣[1] 张勇学[1] 龚昆梅[1] 肖乐[1] 凌平[1] 

机构地区：[1]云南省第一人民医院普通外科,云南昆明650032

出　　处：《中外医疗》2008年第32期8-10,共3页China & Foreign Medical Treatment

摘　　要：目的探索有效的口服希罗达和静脉注射奥沙利铂(L-OHP)治疗结直肠癌的给药方案。方法中晚期结直肠癌患者49例,疗程第1天和第8天,L-OHP70mg/m2静脉泵持续8:00am～8:00pm匀速泵入;希罗达总量1750mg/(m2·d),分为总量的1/4、1/4、1/2剂量分别于每天8:00am、16:00pm和10:00pm分次口服。14d为1个疗程,每间隔21d重复同样的疗程。结果治疗期间完全有效8.2%,部分有效57.1%,总的有效率66.3%,疾病稳定30.6%和无效率均为4.1%,控制率95.9%,中位疾病进展和中位总体生存时间分别达到8个月和26.7个月;不良反应以神经、消化道和骨髓毒性为主,多为1～2级,未出现4级毒性反应。结论调整希罗达加奥沙利铂给药时间对中晚期结直肠癌化疗效果具有积极意义。Objective To define the feasibility and effiency of XELOX administered through chronomedu-lated schedule in advanced colorectal cancer （CRC） patients. Methods 49 patients with advanced CRC were treated as follow： oxaliplatin 70 mg/m^2 continuous infusion from8：00am to 8：00pm on days 1,8 plus chronomodulated oral capecitabine 1,750 mg/（m^2· d） （8：00am 25% of total dose： 16：00pro 25% of total dose： 11：00 pm 50% of total dose） from days 1-14,and every 21 days was a cycle. Results The Objective response and stable disease were recorded in 32（65.3%） and in 2 patients （4.1%）,respectively.The median time to progression（TTP） was 8 months（95℃[：6.0-10.2 months）. The overall survival （OS） was not reached,with a median value〉26 months （95% CI： 24.9-37.3 months）. The toxicities were mainly grade 0-3,and no grade 4 appeared.Conclusion This regimen resulted of particular benefit for patients with advanced CRC.

关 键 词：希罗达 奥沙利铂 给药时间 中晚期结直肠癌 

分 类 号：R735[医药卫生—肿瘤]